ArticleKidney international reports2026
Kidney Tertiary Lymphoid Tissues and Poor Immunosuppressive Response in IgA Nephropathy.
Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Association of Urinary Soluble CD163 With Response to Immunosuppressive Therapy and Renal Relapse in IgAN.Kidney international reports · 2026Article
- Inflammation-Driven Lymphoid Structures: Organization, Function, and Clinical Impact Across Autoimmunity, Cancer, and Checkpoint Toxicity.Immunological reviews · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Ectopic lymphoid structures termed as tertiary lymphoid tissues (TLTs) are observed in certain kidney diseases, including IgA nephropathy (IgAN); however, clinical relevance of TLTs remains unclear. Methods: This prospective cohort study included 845 Chinese patients with IgAN with proteinuria ≥ 1 g/d despite 3 months of optimized supportive care with renin-angiotensin system inhibitors. Patients received immunosuppression for a median of 22 months. Kidney interstitial TLTs, defined as lymphocyte aggregates, were counted using immunochemistry and staged by the absence (stage I) or presence of follicular dendritic cells (FDCs) (stage II) or germinal centers (GCs) (stage III). The outcome was response to immunosuppression, defined as no remission with up to 12 months of immunosuppression. Results: Kidney interstitial TLTs were present in 429 of 845 patients with IgAN (50.8%), of whom 72 of 429 (16.8%) had TLTs at advanced stages (stage II or III). Compared with patients without TLTs, both the presence and stage of TLTs were associated with significantly increased risk of poor response to immunosuppression, with an adjusted odds ratio (95% confidence interval [CI]) of 3.07 (2.16-4.37), 2.97 (2.05-4.28), and 6.25 (3.39-11.53) in those with TLTs at any stage, stage I, and advanced stage, respectively. This grade association remained consistent across all prespecified subgroups. The stage and number of TLTs predicted poor response to immunosuppression with an area under receiver operating characteristic curve (AUC) of 0.81 (95% CI: 0.75-0.87). The AUC increased to 0.90 (95% CI: 0.87-0.94) when we combined TLTs with the clinical and glomerular macrophage data at biopsy. Conclusion: The presence of interstitial TLTs at diagnosis was associated with poor response to immunosuppression in IgAN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.